Clinical Trial: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Brief Summary: The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).
Detailed Summary:
Sponsor: Innate Pharma
Current Primary Outcome: Occurrence of Dose Limiting Toxicities (DLT) [ Time Frame: Within 2 weeks after the first administration ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Innate Pharma
Dates:
Date Received: October 29, 2015
Date Started: October 2015
Date Completion: December 2019
Last Updated: March 2, 2017
Last Verified: March 2017